Market Outlook
The global Biopharmaceutical CDMO Service market size was valued at USD 15060 million in 2022 and is forecast to a readjusted size of USD 29010 million by 2029 with a CAGR of 9.8% during review period.
Report includes an overview of the development of the Biopharmaceutical CDMO Service industry chain, the market status of Pharmaceutical Company (Develop Innovative Drugs, Listed Patented Drug), Biotechnology Company (Develop Innovative Drugs, Listed Patented Drug), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Biopharmaceutical CDMO Service.
Regionally, the report analyzes the Biopharmaceutical CDMO Service markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Biopharmaceutical CDMO Service market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Biopharmaceutical CDMO Service market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Biopharmaceutical CDMO Service industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Develop Innovative Drugs, Listed Patented Drug).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Biopharmaceutical CDMO Service market.
Regional Analysis: The report involves examining the Biopharmaceutical CDMO Service market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Biopharmaceutical CDMO Service market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Biopharmaceutical CDMO Service:
Company Analysis: Report covers individual Biopharmaceutical CDMO Service players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Biopharmaceutical CDMO Service This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Pharmaceutical Company, Biotechnology Company).
Technology Analysis: Report covers specific technologies relevant to Biopharmaceutical CDMO Service. It assesses the current state, advancements, and potential future developments in Biopharmaceutical CDMO Service areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Biopharmaceutical CDMO Service market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Key Market Players
KBI Biopharma
INCOG BioPharma Services
CordenPharma
AGC Biologics
Northway Biotech
PlantForm Corp
Lonza
ADL Biopharma
Catalent
Future Fields
Vetter Pharma
Stelis
Richter-Helm
FUJIFILM Diosynth Biotechnologies
Cambrex
Pfizer CentreOne
Samsung Biologics
Segmentation By Type
Develop Innovative Drugs
Listed Patented Drug
Biosimilars
Others
Segmentation By Application
Pharmaceutical Company
Biotechnology Company
Others
Segmentation By Region
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Market SWOT Analysis
What are the strengths of the biopharmaceutical CDMO service market in 2025?
The biopharmaceutical CDMO (Contract Development and Manufacturing Organization) market benefits from strong demand for innovative therapies, such as biologics and cell and gene therapies. Companies increasingly prefer outsourcing due to cost efficiency, access to specialized expertise, and faster time-to-market. Additionally, CDMOs have heavily invested in state-of-the-art manufacturing capabilities and quality assurance systems, making them reliable partners for biopharma companies.
What weaknesses might the market face?
The market is challenged by high competition, which can pressure pricing and profitability. Limited capacity in specialized segments, such as high-potency API manufacturing or viral vector production, could create bottlenecks. Regulatory complexities and risks associated with quality compliance are ongoing concerns, as a single lapse can damage reputation and client trust.
What opportunities exist for the biopharmaceutical CDMO service market in 2025?
Growing investments in personalized medicine, biosimilars, and mRNA-based therapies present significant growth opportunities. Expanding geographic demand in emerging markets, coupled with increased biopharma R&D spending, creates potential for CDMOs to enter new regions and diversify their service portfolios. Strategic partnerships with biotech startups can also unlock innovation-driven opportunities.
What threats could the market encounter?
Economic uncertainty and geopolitical tensions could impact global supply chains and operational costs. Additionally, technological advancements in bioprocessing might lead some biopharma companies to insource certain capabilities, reducing dependency on CDMOs. Increasingly stringent regulatory environments and patent cliffs for blockbuster drugs could further complicate the market dynamics.
Market PESTEL Analysis
How do political factors influence the biopharmaceutical CDMO service market in 2025?
Political stability and supportive healthcare policies in key regions, such as the U.S. and Europe, create a conducive environment for CDMO growth. However, geopolitical tensions and trade regulations can disrupt global supply chains and increase operational risks.
How do economic factors affect the market?
Economic growth in emerging markets drives biopharma investments, creating opportunities for CDMOs to expand. However, inflation, fluctuating exchange rates, and high operational costs could pressure profit margins, especially for smaller players.
How do social factors shape the market?
Increasing global healthcare awareness and demand for advanced therapies like biologics enhance the need for CDMO services. The aging population and rising prevalence of chronic diseases further boost demand for biopharmaceuticals, strengthening the market's growth prospects.
How do technological factors impact the market?
Advancements in bioprocessing technologies, such as single-use systems and automation, improve manufacturing efficiency and scalability. However, the rapid pace of innovation requires CDMOs to continually invest in upgrading infrastructure, which can be capital-intensive.
How do environmental factors play a role?
The growing emphasis on sustainable practices in the biopharma industry pushes CDMOs to adopt green manufacturing technologies and reduce carbon footprints. Failure to align with environmental standards may lead to reputational risks and regulatory penalties.
How do legal factors influence the market?
Strict regulatory frameworks for biopharmaceutical manufacturing, including GMP compliance and safety standards, significantly impact CDMO operations. Adapting to evolving legal requirements is essential, as non-compliance can result in penalties, delays, and loss of client trust.
Market SIPOC Analysis
Who are the suppliers in the biopharmaceutical CDMO service market in 2025?
Suppliers include raw material providers for APIs (active pharmaceutical ingredients), specialized equipment manufacturers, packaging suppliers, and service providers offering analytical testing, regulatory guidance, and logistics support. Key suppliers are those offering advanced technologies for drug development and manufacturing processes.
Who are the inputs for the biopharmaceutical CDMO service market?
The primary inputs are raw materials, such as APIs, excipients, and bioreactor components. Additionally, technical expertise in drug development, regulatory knowledge, and skilled labor in areas like quality assurance, project management, and production are crucial inputs for CDMOs.
What are the processes involved in the biopharmaceutical CDMO service market?
The processes involve contract development, formulation, clinical trial material production, scale-up manufacturing, and packaging. Each process requires adherence to stringent regulatory standards, quality control, and optimization of biomanufacturing technologies to meet clients' needs.
Who are the customers in this market?
Customers include biopharmaceutical companies, both large and small, across various therapeutic areas such as oncology, immunology, and rare diseases. Biotech startups, research organizations, and pharmaceutical companies seeking outsourcing for drug development and manufacturing are key clients.
What are the outputs of the biopharmaceutical CDMO service market?
The primary outputs are high-quality, compliant biopharmaceutical products, including biologics, biosimilars, vaccines, and cell and gene therapies. These outputs are ready for commercialization and distribution, ensuring efficient supply chains and meeting market demands.
Market Porter's Five Forces
What is the threat of new entrants in the biopharmaceutical CDMO service market in 2025?
The threat of new entrants is moderate to low. Although the market is growing, the significant capital investment required for advanced manufacturing facilities, strict regulatory compliance, and technical expertise creates high barriers to entry for new players.
What is the bargaining power of suppliers in this market?
The bargaining power of suppliers is moderate. While there are many suppliers of raw materials and equipment, the growing demand for specialized, high-quality biopharmaceutical components increases their leverage. However, CDMOs can mitigate this power by diversifying their supplier base and establishing long-term relationships.
What is the bargaining power of buyers in the biopharmaceutical CDMO service market?
The bargaining power of buyers is moderate to high. As the number of CDMOs grows, pharmaceutical companies have more options to choose from, which increases their bargaining power. However, the need for specialized services and high-quality production limits buyers' ability to switch freely between service providers.
What is the threat of substitute products or services in this market?
The threat of substitutes is low. The highly specialized and regulated nature of biopharmaceutical manufacturing creates limited alternatives to CDMOs. Although some larger pharmaceutical companies may consider bringing production in-house, the complexity and scale of modern biomanufacturing often make outsourcing a more cost-effective option.
What is the intensity of competitive rivalry in the biopharmaceutical CDMO service market?
The intensity of competitive rivalry is high. The market is fragmented, with both large multinational players and smaller, niche CDMOs competing for market share. Continuous innovation, cost efficiency, and high-quality service are key differentiators in this competitive landscape.
Market Upstream Analysis
What are the key upstream factors influencing the biopharmaceutical CDMO service market in 2025?
Upstream factors include the availability and cost of raw materials, such as active pharmaceutical ingredients (APIs), excipients, and bioreactor components. Additionally, advances in upstream biomanufacturing technologies, like cell culture systems and fermentation processes, play a critical role in determining the efficiency and scalability of production.
How do raw material suppliers affect the biopharmaceutical CDMO service market?
Raw material suppliers have a significant impact, as the quality and availability of ingredients, such as biologics and specialized reagents, directly influence the production capabilities of CDMOs. Supply chain disruptions or volatility in raw material prices can lead to delays and cost fluctuations, impacting service delivery.
How do technology developments in upstream processes affect the market?
Advancements in upstream bioprocessing technologies, such as improved cell lines, bioreactor systems, and high-throughput screening, enable CDMOs to optimize production efficiency and reduce costs. These technological developments drive the scalability of manufacturing and support the growing demand for complex therapies like biologics and gene therapies.
How do regulatory changes impact the upstream segment of the market?
Regulatory changes, such as stricter guidelines on the manufacturing and sourcing of raw materials, directly impact the upstream segment. Compliance with evolving standards ensures product safety but may increase the time and cost of development. CDMOs must adapt to these changes to remain competitive and avoid regulatory penalties.
Market Midstream Analysis
What are the key midstream factors influencing the biopharmaceutical CDMO service market in 2025?
Midstream factors in the biopharmaceutical CDMO service market include the actual manufacturing processes, such as the scale-up of production from clinical trials to commercial manufacturing. This phase involves the critical operations of formulation, aseptic processing, and packaging, which must meet stringent regulatory and quality control standards.
How does the manufacturing process impact the biopharmaceutical CDMO service market?
The efficiency and flexibility of the manufacturing process are key to meeting the growing demand for complex therapies. Advances in continuous manufacturing, automation, and single-use technologies allow CDMOs to scale production quickly and maintain high product quality, thus increasing their competitiveness in the market.
How do quality control and regulatory compliance affect the midstream segment?
Quality control and regulatory compliance are crucial in the midstream phase, as CDMOs must ensure that manufacturing processes meet both local and international regulatory standards, such as cGMP. Failure to comply with these regulations can lead to production delays, increased costs, and reputational damage.
How do logistics and supply chain management influence midstream operations?
Logistics and supply chain management play a pivotal role in ensuring the timely delivery of materials and final products. Efficient logistics enable CDMOs to maintain a steady flow of raw materials for production and ensure that finished products are distributed promptly to meet market demand. However, disruptions in the supply chain can impact production timelines and cost efficiency.
Market Downstream Analysis
What are the key downstream factors influencing the biopharmaceutical CDMO service market in 2025?
Downstream factors in the biopharmaceutical CDMO service market include final product packaging, distribution, and post-production services like regulatory filing and market access. The ability to efficiently package, store, and deliver products, while ensuring compliance with various regulations, is crucial to the success of CDMOs in the downstream phase.
How does product commercialization affect the biopharmaceutical CDMO service market?
Product commercialization is a key driver for CDMOs, as it involves preparing therapies for large-scale distribution. The ability to swiftly move from small-scale manufacturing to large-scale commercial production is vital. CDMOs that can manage this transition effectively help their clients bring products to market faster, which is a significant competitive advantage.
How does market access and regulatory approval impact the downstream segment?
Achieving market access and regulatory approval is essential for product success. CDMOs play a critical role in ensuring that all regulatory requirements are met during the final stages of manufacturing. Delays in regulatory approval or market access can hinder product launch and affect CDMOs’ timelines and profitability.
How do customer support and post-manufacturing services affect the downstream operations?
Customer support and post-manufacturing services, such as handling product recalls, providing technical support, and managing ongoing quality assurance, are critical for maintaining client relationships and ensuring long-term success. CDMOs that offer comprehensive post-manufacturing services help ensure the continued safety and efficacy of the products they produce, enhancing their value proposition to clients.
Chapter 1, to describe Biopharmaceutical CDMO Service product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Biopharmaceutical CDMO Service, with revenue, gross margin and global market share of Biopharmaceutical CDMO Service from 2018 to 2023.
Chapter 3, the Biopharmaceutical CDMO Service competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Biopharmaceutical CDMO Service market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Biopharmaceutical CDMO Service.
Chapter 13, to describe Biopharmaceutical CDMO Service research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Biopharmaceutical CDMO Service
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Biopharmaceutical CDMO Service by Type
1.3.1 Overview: Global Biopharmaceutical CDMO Service Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Biopharmaceutical CDMO Service Consumption Value Market Share by Type in 2022
1.3.3 Develop Innovative Drugs
1.3.4 Listed Patented Drug
1.3.5 Biosimilars
1.3.6 Others
1.4 Global Biopharmaceutical CDMO Service Market by Application
1.4.1 Overview: Global Biopharmaceutical CDMO Service Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Pharmaceutical Company
1.4.3 Biotechnology Company
1.4.4 Others
1.5 Global Biopharmaceutical CDMO Service Market Size & Forecast
1.6 Global Biopharmaceutical CDMO Service Market Size and Forecast by Region
1.6.1 Global Biopharmaceutical CDMO Service Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Biopharmaceutical CDMO Service Market Size by Region, (2018-2029)
1.6.3 North America Biopharmaceutical CDMO Service Market Size and Prospect (2018-2029)
1.6.4 Europe Biopharmaceutical CDMO Service Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Biopharmaceutical CDMO Service Market Size and Prospect (2018-2029)
1.6.6 South America Biopharmaceutical CDMO Service Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Biopharmaceutical CDMO Service Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 KBI Biopharma
2.1.1 KBI Biopharma Details
2.1.2 KBI Biopharma Major Business
2.1.3 KBI Biopharma Biopharmaceutical CDMO Service Product and Solutions
2.1.4 KBI Biopharma Biopharmaceutical CDMO Service Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 KBI Biopharma Recent Developments and Future Plans
2.2 INCOG BioPharma Services
2.2.1 INCOG BioPharma Services Details
2.2.2 INCOG BioPharma Services Major Business
2.2.3 INCOG BioPharma Services Biopharmaceutical CDMO Service Product and Solutions
2.2.4 INCOG BioPharma Services Biopharmaceutical CDMO Service Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 INCOG BioPharma Services Recent Developments and Future Plans
2.3 CordenPharma
2.3.1 CordenPharma Details
2.3.2 CordenPharma Major Business
2.3.3 CordenPharma Biopharmaceutical CDMO Service Product and Solutions
2.3.4 CordenPharma Biopharmaceutical CDMO Service Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 CordenPharma Recent Developments and Future Plans
2.4 AGC Biologics
2.4.1 AGC Biologics Details
2.4.2 AGC Biologics Major Business
2.4.3 AGC Biologics Biopharmaceutical CDMO Service Product and Solutions
2.4.4 AGC Biologics Biopharmaceutical CDMO Service Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 AGC Biologics Recent Developments and Future Plans
2.5 Northway Biotech
2.5.1 Northway Biotech Details
2.5.2 Northway Biotech Major Business
2.5.3 Northway Biotech Biopharmaceutical CDMO Service Product and Solutions
2.5.4 Northway Biotech Biopharmaceutical CDMO Service Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Northway Biotech Recent Developments and Future Plans
2.6 PlantForm Corp
2.6.1 PlantForm Corp Details
2.6.2 PlantForm Corp Major Business
2.6.3 PlantForm Corp Biopharmaceutical CDMO Service Product and Solutions
2.6.4 PlantForm Corp Biopharmaceutical CDMO Service Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 PlantForm Corp Recent Developments and Future Plans
2.7 Lonza
2.7.1 Lonza Details
2.7.2 Lonza Major Business
2.7.3 Lonza Biopharmaceutical CDMO Service Product and Solutions
2.7.4 Lonza Biopharmaceutical CDMO Service Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Lonza Recent Developments and Future Plans
2.8 ADL Biopharma
2.8.1 ADL Biopharma Details
2.8.2 ADL Biopharma Major Business
2.8.3 ADL Biopharma Biopharmaceutical CDMO Service Product and Solutions
2.8.4 ADL Biopharma Biopharmaceutical CDMO Service Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 ADL Biopharma Recent Developments and Future Plans
2.9 Catalent
2.9.1 Catalent Details
2.9.2 Catalent Major Business
2.9.3 Catalent Biopharmaceutical CDMO Service Product and Solutions
2.9.4 Catalent Biopharmaceutical CDMO Service Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Catalent Recent Developments and Future Plans
2.10 Future Fields
2.10.1 Future Fields Details
2.10.2 Future Fields Major Business
2.10.3 Future Fields Biopharmaceutical CDMO Service Product and Solutions
2.10.4 Future Fields Biopharmaceutical CDMO Service Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Future Fields Recent Developments and Future Plans
2.11 Vetter Pharma
2.11.1 Vetter Pharma Details
2.11.2 Vetter Pharma Major Business
2.11.3 Vetter Pharma Biopharmaceutical CDMO Service Product and Solutions
2.11.4 Vetter Pharma Biopharmaceutical CDMO Service Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Vetter Pharma Recent Developments and Future Plans
2.12 Stelis
2.12.1 Stelis Details
2.12.2 Stelis Major Business
2.12.3 Stelis Biopharmaceutical CDMO Service Product and Solutions
2.12.4 Stelis Biopharmaceutical CDMO Service Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Stelis Recent Developments and Future Plans
2.13 Richter-Helm
2.13.1 Richter-Helm Details
2.13.2 Richter-Helm Major Business
2.13.3 Richter-Helm Biopharmaceutical CDMO Service Product and Solutions
2.13.4 Richter-Helm Biopharmaceutical CDMO Service Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Richter-Helm Recent Developments and Future Plans
2.14 FUJIFILM Diosynth Biotechnologies
2.14.1 FUJIFILM Diosynth Biotechnologies Details
2.14.2 FUJIFILM Diosynth Biotechnologies Major Business
2.14.3 FUJIFILM Diosynth Biotechnologies Biopharmaceutical CDMO Service Product and Solutions
2.14.4 FUJIFILM Diosynth Biotechnologies Biopharmaceutical CDMO Service Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans
2.15 Cambrex
2.15.1 Cambrex Details
2.15.2 Cambrex Major Business
2.15.3 Cambrex Biopharmaceutical CDMO Service Product and Solutions
2.15.4 Cambrex Biopharmaceutical CDMO Service Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Cambrex Recent Developments and Future Plans
2.16 Pfizer CentreOne
2.16.1 Pfizer CentreOne Details
2.16.2 Pfizer CentreOne Major Business
2.16.3 Pfizer CentreOne Biopharmaceutical CDMO Service Product and Solutions
2.16.4 Pfizer CentreOne Biopharmaceutical CDMO Service Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Pfizer CentreOne Recent Developments and Future Plans
2.17 Samsung Biologics
2.17.1 Samsung Biologics Details
2.17.2 Samsung Biologics Major Business
2.17.3 Samsung Biologics Biopharmaceutical CDMO Service Product and Solutions
2.17.4 Samsung Biologics Biopharmaceutical CDMO Service Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Samsung Biologics Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Biopharmaceutical CDMO Service Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Biopharmaceutical CDMO Service by Company Revenue
3.2.2 Top 3 Biopharmaceutical CDMO Service Players Market Share in 2022
3.2.3 Top 6 Biopharmaceutical CDMO Service Players Market Share in 2022
3.3 Biopharmaceutical CDMO Service Market: Overall Company Footprint Analysis
3.3.1 Biopharmaceutical CDMO Service Market: Region Footprint
3.3.2 Biopharmaceutical CDMO Service Market: Company Product Type Footprint
3.3.3 Biopharmaceutical CDMO Service Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Biopharmaceutical CDMO Service Consumption Value and Market Share by Type (2018-2023)
4.2 Global Biopharmaceutical CDMO Service Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Biopharmaceutical CDMO Service Consumption Value Market Share by Application (2018-2023)
5.2 Global Biopharmaceutical CDMO Service Market Forecast by Application (2024-2029)
6 North America
6.1 North America Biopharmaceutical CDMO Service Consumption Value by Type (2018-2029)
6.2 North America Biopharmaceutical CDMO Service Consumption Value by Application (2018-2029)
6.3 North America Biopharmaceutical CDMO Service Market Size by Country
6.3.1 North America Biopharmaceutical CDMO Service Consumption Value by Country (2018-2029)
6.3.2 United States Biopharmaceutical CDMO Service Market Size and Forecast (2018-2029)
6.3.3 Canada Biopharmaceutical CDMO Service Market Size and Forecast (2018-2029)
6.3.4 Mexico Biopharmaceutical CDMO Service Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Biopharmaceutical CDMO Service Consumption Value by Type (2018-2029)
7.2 Europe Biopharmaceutical CDMO Service Consumption Value by Application (2018-2029)
7.3 Europe Biopharmaceutical CDMO Service Market Size by Country
7.3.1 Europe Biopharmaceutical CDMO Service Consumption Value by Country (2018-2029)
7.3.2 Germany Biopharmaceutical CDMO Service Market Size and Forecast (2018-2029)
7.3.3 France Biopharmaceutical CDMO Service Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Biopharmaceutical CDMO Service Market Size and Forecast (2018-2029)
7.3.5 Russia Biopharmaceutical CDMO Service Market Size and Forecast (2018-2029)
7.3.6 Italy Biopharmaceutical CDMO Service Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Biopharmaceutical CDMO Service Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Biopharmaceutical CDMO Service Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Biopharmaceutical CDMO Service Market Size by Region
8.3.1 Asia-Pacific Biopharmaceutical CDMO Service Consumption Value by Region (2018-2029)
8.3.2 China Biopharmaceutical CDMO Service Market Size and Forecast (2018-2029)
8.3.3 Japan Biopharmaceutical CDMO Service Market Size and Forecast (2018-2029)
8.3.4 South Korea Biopharmaceutical CDMO Service Market Size and Forecast (2018-2029)
8.3.5 India Biopharmaceutical CDMO Service Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Biopharmaceutical CDMO Service Market Size and Forecast (2018-2029)
8.3.7 Australia Biopharmaceutical CDMO Service Market Size and Forecast (2018-2029)
9 South America
9.1 South America Biopharmaceutical CDMO Service Consumption Value by Type (2018-2029)
9.2 South America Biopharmaceutical CDMO Service Consumption Value by Application (2018-2029)
9.3 South America Biopharmaceutical CDMO Service Market Size by Country
9.3.1 South America Biopharmaceutical CDMO Service Consumption Value by Country (2018-2029)
9.3.2 Brazil Biopharmaceutical CDMO Service Market Size and Forecast (2018-2029)
9.3.3 Argentina Biopharmaceutical CDMO Service Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Biopharmaceutical CDMO Service Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Biopharmaceutical CDMO Service Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Biopharmaceutical CDMO Service Market Size by Country
10.3.1 Middle East & Africa Biopharmaceutical CDMO Service Consumption Value by Country (2018-2029)
10.3.2 Turkey Biopharmaceutical CDMO Service Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Biopharmaceutical CDMO Service Market Size and Forecast (2018-2029)
10.3.4 UAE Biopharmaceutical CDMO Service Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Biopharmaceutical CDMO Service Market Drivers
11.2 Biopharmaceutical CDMO Service Market Restraints
11.3 Biopharmaceutical CDMO Service Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Biopharmaceutical CDMO Service Industry Chain
12.2 Biopharmaceutical CDMO Service Upstream Analysis
12.3 Biopharmaceutical CDMO Service Midstream Analysis
12.4 Biopharmaceutical CDMO Service Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Biopharmaceutical CDMO Service Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Biopharmaceutical CDMO Service Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Biopharmaceutical CDMO Service Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Biopharmaceutical CDMO Service Consumption Value by Region (2024-2029) & (USD Million)
Table 5. KBI Biopharma Company Information, Head Office, and Major Competitors
Table 6. KBI Biopharma Major Business
Table 7. KBI Biopharma Biopharmaceutical CDMO Service Product and Solutions
Table 8. KBI Biopharma Biopharmaceutical CDMO Service Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. KBI Biopharma Recent Developments and Future Plans
Table 10. INCOG BioPharma Services Company Information, Head Office, and Major Competitors
Table 11. INCOG BioPharma Services Major Business
Table 12. INCOG BioPharma Services Biopharmaceutical CDMO Service Product and Solutions
Table 13. INCOG BioPharma Services Biopharmaceutical CDMO Service Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. INCOG BioPharma Services Recent Developments and Future Plans
Table 15. CordenPharma Company Information, Head Office, and Major Competitors
Table 16. CordenPharma Major Business
Table 17. CordenPharma Biopharmaceutical CDMO Service Product and Solutions
Table 18. CordenPharma Biopharmaceutical CDMO Service Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. CordenPharma Recent Developments and Future Plans
Table 20. AGC Biologics Company Information, Head Office, and Major Competitors
Table 21. AGC Biologics Major Business
Table 22. AGC Biologics Biopharmaceutical CDMO Service Product and Solutions
Table 23. AGC Biologics Biopharmaceutical CDMO Service Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. AGC Biologics Recent Developments and Future Plans
Table 25. Northway Biotech Company Information, Head Office, and Major Competitors
Table 26. Northway Biotech Major Business
Table 27. Northway Biotech Biopharmaceutical CDMO Service Product and Solutions
Table 28. Northway Biotech Biopharmaceutical CDMO Service Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Northway Biotech Recent Developments and Future Plans
Table 30. PlantForm Corp Company Information, Head Office, and Major Competitors
Table 31. PlantForm Corp Major Business
Table 32. PlantForm Corp Biopharmaceutical CDMO Service Product and Solutions
Table 33. PlantForm Corp Biopharmaceutical CDMO Service Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. PlantForm Corp Recent Developments and Future Plans
Table 35. Lonza Company Information, Head Office, and Major Competitors
Table 36. Lonza Major Business
Table 37. Lonza Biopharmaceutical CDMO Service Product and Solutions
Table 38. Lonza Biopharmaceutical CDMO Service Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Lonza Recent Developments and Future Plans
Table 40. ADL Biopharma Company Information, Head Office, and Major Competitors
Table 41. ADL Biopharma Major Business
Table 42. ADL Biopharma Biopharmaceutical CDMO Service Product and Solutions
Table 43. ADL Biopharma Biopharmaceutical CDMO Service Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. ADL Biopharma Recent Developments and Future Plans
Table 45. Catalent Company Information, Head Office, and Major Competitors
Table 46. Catalent Major Business
Table 47. Catalent Biopharmaceutical CDMO Service Product and Solutions
Table 48. Catalent Biopharmaceutical CDMO Service Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Catalent Recent Developments and Future Plans
Table 50. Future Fields Company Information, Head Office, and Major Competitors
Table 51. Future Fields Major Business
Table 52. Future Fields Biopharmaceutical CDMO Service Product and Solutions
Table 53. Future Fields Biopharmaceutical CDMO Service Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Future Fields Recent Developments and Future Plans
Table 55. Vetter Pharma Company Information, Head Office, and Major Competitors
Table 56. Vetter Pharma Major Business
Table 57. Vetter Pharma Biopharmaceutical CDMO Service Product and Solutions
Table 58. Vetter Pharma Biopharmaceutical CDMO Service Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Vetter Pharma Recent Developments and Future Plans
Table 60. Stelis Company Information, Head Office, and Major Competitors
Table 61. Stelis Major Business
Table 62. Stelis Biopharmaceutical CDMO Service Product and Solutions
Table 63. Stelis Biopharmaceutical CDMO Service Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Stelis Recent Developments and Future Plans
Table 65. Richter-Helm Company Information, Head Office, and Major Competitors
Table 66. Richter-Helm Major Business
Table 67. Richter-Helm Biopharmaceutical CDMO Service Product and Solutions
Table 68. Richter-Helm Biopharmaceutical CDMO Service Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Richter-Helm Recent Developments and Future Plans
Table 70. FUJIFILM Diosynth Biotechnologies Company Information, Head Office, and Major Competitors
Table 71. FUJIFILM Diosynth Biotechnologies Major Business
Table 72. FUJIFILM Diosynth Biotechnologies Biopharmaceutical CDMO Service Product and Solutions
Table 73. FUJIFILM Diosynth Biotechnologies Biopharmaceutical CDMO Service Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans
Table 75. Cambrex Company Information, Head Office, and Major Competitors
Table 76. Cambrex Major Business
Table 77. Cambrex Biopharmaceutical CDMO Service Product and Solutions
Table 78. Cambrex Biopharmaceutical CDMO Service Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Cambrex Recent Developments and Future Plans
Table 80. Pfizer CentreOne Company Information, Head Office, and Major Competitors
Table 81. Pfizer CentreOne Major Business
Table 82. Pfizer CentreOne Biopharmaceutical CDMO Service Product and Solutions
Table 83. Pfizer CentreOne Biopharmaceutical CDMO Service Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 84. Pfizer CentreOne Recent Developments and Future Plans
Table 85. Samsung Biologics Company Information, Head Office, and Major Competitors
Table 86. Samsung Biologics Major Business
Table 87. Samsung Biologics Biopharmaceutical CDMO Service Product and Solutions
Table 88. Samsung Biologics Biopharmaceutical CDMO Service Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Samsung Biologics Recent Developments and Future Plans
Table 90. Global Biopharmaceutical CDMO Service Revenue (USD Million) by Players (2018-2023)
Table 91. Global Biopharmaceutical CDMO Service Revenue Share by Players (2018-2023)
Table 92. Breakdown of Biopharmaceutical CDMO Service by Company Type (Tier 1, Tier 2, and Tier 3)
Table 93. Market Position of Players in Biopharmaceutical CDMO Service, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 94. Head Office of Key Biopharmaceutical CDMO Service Players
Table 95. Biopharmaceutical CDMO Service Market: Company Product Type Footprint
Table 96. Biopharmaceutical CDMO Service Market: Company Product Application Footprint
Table 97. Biopharmaceutical CDMO Service New Market Entrants and Barriers to Market Entry
Table 98. Biopharmaceutical CDMO Service Mergers, Acquisition, Agreements, and Collaborations
Table 99. Global Biopharmaceutical CDMO Service Consumption Value (USD Million) by Type (2018-2023)
Table 100. Global Biopharmaceutical CDMO Service Consumption Value Share by Type (2018-2023)
Table 101. Global Biopharmaceutical CDMO Service Consumption Value Forecast by Type (2024-2029)
Table 102. Global Biopharmaceutical CDMO Service Consumption Value by Application (2018-2023)
Table 103. Global Biopharmaceutical CDMO Service Consumption Value Forecast by Application (2024-2029)
Table 104. North America Biopharmaceutical CDMO Service Consumption Value by Type (2018-2023) & (USD Million)
Table 105. North America Biopharmaceutical CDMO Service Consumption Value by Type (2024-2029) & (USD Million)
Table 106. North America Biopharmaceutical CDMO Service Consumption Value by Application (2018-2023) & (USD Million)
Table 107. North America Biopharmaceutical CDMO Service Consumption Value by Application (2024-2029) & (USD Million)
Table 108. North America Biopharmaceutical CDMO Service Consumption Value by Country (2018-2023) & (USD Million)
Table 109. North America Biopharmaceutical CDMO Service Consumption Value by Country (2024-2029) & (USD Million)
Table 110. Europe Biopharmaceutical CDMO Service Consumption Value by Type (2018-2023) & (USD Million)
Table 111. Europe Biopharmaceutical CDMO Service Consumption Value by Type (2024-2029) & (USD Million)
Table 112. Europe Biopharmaceutical CDMO Service Consumption Value by Application (2018-2023) & (USD Million)
Table 113. Europe Biopharmaceutical CDMO Service Consumption Value by Application (2024-2029) & (USD Million)
Table 114. Europe Biopharmaceutical CDMO Service Consumption Value by Country (2018-2023) & (USD Million)
Table 115. Europe Biopharmaceutical CDMO Service Consumption Value by Country (2024-2029) & (USD Million)
Table 116. Asia-Pacific Biopharmaceutical CDMO Service Consumption Value by Type (2018-2023) & (USD Million)
Table 117. Asia-Pacific Biopharmaceutical CDMO Service Consumption Value by Type (2024-2029) & (USD Million)
Table 118. Asia-Pacific Biopharmaceutical CDMO Service Consumption Value by Application (2018-2023) & (USD Million)
Table 119. Asia-Pacific Biopharmaceutical CDMO Service Consumption Value by Application (2024-2029) & (USD Million)
Table 120. Asia-Pacific Biopharmaceutical CDMO Service Consumption Value by Region (2018-2023) & (USD Million)
Table 121. Asia-Pacific Biopharmaceutical CDMO Service Consumption Value by Region (2024-2029) & (USD Million)
Table 122. South America Biopharmaceutical CDMO Service Consumption Value by Type (2018-2023) & (USD Million)
Table 123. South America Biopharmaceutical CDMO Service Consumption Value by Type (2024-2029) & (USD Million)
Table 124. South America Biopharmaceutical CDMO Service Consumption Value by Application (2018-2023) & (USD Million)
Table 125. South America Biopharmaceutical CDMO Service Consumption Value by Application (2024-2029) & (USD Million)
Table 126. South America Biopharmaceutical CDMO Service Consumption Value by Country (2018-2023) & (USD Million)
Table 127. South America Biopharmaceutical CDMO Service Consumption Value by Country (2024-2029) & (USD Million)
Table 128. Middle East & Africa Biopharmaceutical CDMO Service Consumption Value by Type (2018-2023) & (USD Million)
Table 129. Middle East & Africa Biopharmaceutical CDMO Service Consumption Value by Type (2024-2029) & (USD Million)
Table 130. Middle East & Africa Biopharmaceutical CDMO Service Consumption Value by Application (2018-2023) & (USD Million)
Table 131. Middle East & Africa Biopharmaceutical CDMO Service Consumption Value by Application (2024-2029) & (USD Million)
Table 132. Middle East & Africa Biopharmaceutical CDMO Service Consumption Value by Country (2018-2023) & (USD Million)
Table 133. Middle East & Africa Biopharmaceutical CDMO Service Consumption Value by Country (2024-2029) & (USD Million)
Table 134. Biopharmaceutical CDMO Service Raw Material
Table 135. Key Suppliers of Biopharmaceutical CDMO Service Raw Materials
List of Figures
Figure 1. Biopharmaceutical CDMO Service Picture
Figure 2. Global Biopharmaceutical CDMO Service Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Biopharmaceutical CDMO Service Consumption Value Market Share by Type in 2022
Figure 4. Develop Innovative Drugs
Figure 5. Listed Patented Drug
Figure 6. Biosimilars
Figure 7. Others
Figure 8. Global Biopharmaceutical CDMO Service Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 9. Biopharmaceutical CDMO Service Consumption Value Market Share by Application in 2022
Figure 10. Pharmaceutical Company Picture
Figure 11. Biotechnology Company Picture
Figure 12. Others Picture
Figure 13. Global Biopharmaceutical CDMO Service Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Biopharmaceutical CDMO Service Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Market Biopharmaceutical CDMO Service Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 16. Global Biopharmaceutical CDMO Service Consumption Value Market Share by Region (2018-2029)
Figure 17. Global Biopharmaceutical CDMO Service Consumption Value Market Share by Region in 2022
Figure 18. North America Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 20. Asia-Pacific Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 21. South America Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 22. Middle East and Africa Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 23. Global Biopharmaceutical CDMO Service Revenue Share by Players in 2022
Figure 24. Biopharmaceutical CDMO Service Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 25. Global Top 3 Players Biopharmaceutical CDMO Service Market Share in 2022
Figure 26. Global Top 6 Players Biopharmaceutical CDMO Service Market Share in 2022
Figure 27. Global Biopharmaceutical CDMO Service Consumption Value Share by Type (2018-2023)
Figure 28. Global Biopharmaceutical CDMO Service Market Share Forecast by Type (2024-2029)
Figure 29. Global Biopharmaceutical CDMO Service Consumption Value Share by Application (2018-2023)
Figure 30. Global Biopharmaceutical CDMO Service Market Share Forecast by Application (2024-2029)
Figure 31. North America Biopharmaceutical CDMO Service Consumption Value Market Share by Type (2018-2029)
Figure 32. North America Biopharmaceutical CDMO Service Consumption Value Market Share by Application (2018-2029)
Figure 33. North America Biopharmaceutical CDMO Service Consumption Value Market Share by Country (2018-2029)
Figure 34. United States Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 35. Canada Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 36. Mexico Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 37. Europe Biopharmaceutical CDMO Service Consumption Value Market Share by Type (2018-2029)
Figure 38. Europe Biopharmaceutical CDMO Service Consumption Value Market Share by Application (2018-2029)
Figure 39. Europe Biopharmaceutical CDMO Service Consumption Value Market Share by Country (2018-2029)
Figure 40. Germany Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 41. France Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 42. United Kingdom Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 43. Russia Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 44. Italy Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 45. Asia-Pacific Biopharmaceutical CDMO Service Consumption Value Market Share by Type (2018-2029)
Figure 46. Asia-Pacific Biopharmaceutical CDMO Service Consumption Value Market Share by Application (2018-2029)
Figure 47. Asia-Pacific Biopharmaceutical CDMO Service Consumption Value Market Share by Region (2018-2029)
Figure 48. China Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 49. Japan Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 50. South Korea Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 51. India Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 52. Southeast Asia Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 53. Australia Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 54. South America Biopharmaceutical CDMO Service Consumption Value Market Share by Type (2018-2029)
Figure 55. South America Biopharmaceutical CDMO Service Consumption Value Market Share by Application (2018-2029)
Figure 56. South America Biopharmaceutical CDMO Service Consumption Value Market Share by Country (2018-2029)
Figure 57. Brazil Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 58. Argentina Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 59. Middle East and Africa Biopharmaceutical CDMO Service Consumption Value Market Share by Type (2018-2029)
Figure 60. Middle East and Africa Biopharmaceutical CDMO Service Consumption Value Market Share by Application (2018-2029)
Figure 61. Middle East and Africa Biopharmaceutical CDMO Service Consumption Value Market Share by Country (2018-2029)
Figure 62. Turkey Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 63. Saudi Arabia Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 64. UAE Biopharmaceutical CDMO Service Consumption Value (2018-2029) & (USD Million)
Figure 65. Biopharmaceutical CDMO Service Market Drivers
Figure 66. Biopharmaceutical CDMO Service Market Restraints
Figure 67. Biopharmaceutical CDMO Service Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of Biopharmaceutical CDMO Service in 2022
Figure 70. Manufacturing Process Analysis of Biopharmaceutical CDMO Service
Figure 71. Biopharmaceutical CDMO Service Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
